Global Project Head, Immunohematology
Sanofi
Cambridge, Massachusetts, United States
Ahmed Daak, MD, MSc, PhD, DPM/FFPM, EMBA
Dr. Ahmed Daak is a physician-scientist with a multidisciplinary background. He earned his medical degree and MSc in Medical Biochemistry from the University of Khartoum (Sudan), followed by a PhD in Biomedical Science from London Metropolitan University. He also holds a Diploma in Pharmaceutical Medicine (DPM) from the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians (UK), and an Executive MBA from Brown University (US) and Executive MBA and IE Business School (Spain).
Dr. Daak has clinical and research expertise in pathology and hematology, with a particular focus on sickle cell disease (SCD). He is a Fellow of the Faculty of Pharmaceutical Medicine (FFPM) and a Takemi Fellow at the Harvard T.H. Chan School of Public Health (genetic epidemiology).
Dr Daak is an active member of several professional organizations, including:
American Society of Hematology (ASH)
American Society of Gene and Cell Therapy (ASGCT)
International Advisory Board Member of Kumar & Clarkâs Clinical Medicine
Currently, Dr. Daak serves as the Global Project Head (GPH) of Immuno-Hematology at Sanofi, where he leads cross-functional teams in the development of innovative therapies for rare diseases.
Development of Rilzabrutinib for Patients with SCD
Friday, June 6, 2025
4:50 PM - 5:05 PM ET